HealthEquity vs Krystal Biotech

HealthEquity (HQY), health care, and Krystal Biotech (KRYS), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Krystal Biotech is worth $8.8B on the stock market and HealthEquity $8.4B: Krystal Biotech is valued at 5% more. HealthEquity trades at 37.7 times earnings and Krystal Biotech at 40.6; operating margins in their latest fiscal years were 24.6% and 41.5%. Over the past year HealthEquity's share price has moved +1.79% and Krystal Biotech's +45.5%.

Key facts

HealthEquity market value
$8.4B
Krystal Biotech market value
$8.8B
HealthEquity P/E
37.7
Krystal Biotech P/E
40.6
HealthEquity revenue
$1.3BFY to 2026-01-31
Krystal Biotech revenue
$389.1MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

HealthEquity vs Krystal Biotech: every measure side by side
Measure HealthEquity Krystal Biotech
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2026-01-312025-12-31
Size
Market cap$8.4Blower$8.8Bhigher
Revenue$1.3Bhigher$389.1Mlower
Earnings$215.2Mhigher$204.8Mlower
Employees2,814higher295lower
Total assets$3.4Bhigher$1.3Blower
Valuation
P/E37.7lower40.6higher
P/S6.4lower22.7higher
P/B4.2lower6.2higher
Dividend yield0.00%0.00%
Profitability
Operating margin24.6%lower41.5%higher
Balance sheet
Net assets$2.1Bhigher$1.2Blower
Total liabilities$1.3Bhigher$114.2Mlower
Total debt$957.4M—
Cash on hand$318.9Mlower$496.3Mhigher
Price change
Today-2.62%lower+0.22%higher
1 year+1.79%lower+45.5%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

HealthEquity only (1)

Krystal Biotech only (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns HQY

Further comparisons

Learn

Questions and answers

Which is bigger, HealthEquity or Krystal Biotech?

By market value, Krystal Biotech is the larger: $8.8B against $8.4B for HealthEquity. By revenue in its latest fiscal year, HealthEquity is the larger: $1.3B against $389.1M for Krystal Biotech.

Which has the higher P/E ratio?

Krystal Biotech: 40.6, against 37.7 for HealthEquity. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

Krystal Biotech: 41.5%, against 24.6% for HealthEquity. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which superinvestors own both HealthEquity and Krystal Biotech?

None of the tracked superinvestors holds both in their latest 13F filing. 1 holds HealthEquity and 0 hold Krystal Biotech.

Cite this page

Funkfolio, “HealthEquity vs Krystal Biotech”, data as of 18 November 2026. https://funkfolio.com/compare/hqy-vs-krys

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.